Search

Objective: We explored the impact of TeKnO T1D, an online, case‐based, spaced education curriculum about insulin pump and continuous glucose monitor (CGM) use in pediatric type 1 diabetes management. Methods: Pediatric endocrinology fellows (n = 64) were randomized to receive an educational curriculum focused on either insulin pumps or CGMs. Fellows received interactive questions twice weekly via email or mobile app. Median time to completion was 76.5 days. The primary outcome was change in knowledge as measured by performance on multiple‐choice questions (MCQ) from the pre‐test to the post‐test. Results: Forty‐eight of 64 (75%) learners completed the curriculum and assessments. The pump group improved from 35.0 ± 15% on the pre‐test MCQs to 61.1 ± 17% on the post‐test, a 12.2 absolute percentage point greater improvement on pump‐specific items than the CGM group (P =.03). The CGM group improved from 30.3 ± 15% on the pre‐test MCQs to 61.4 ± 21% on the post‐test, a 28.7 absolute percentage point greater improvement on CGM‐specific items than the pump group (P <.001). Both groups were more likely to report an appropriate level of understanding of their respective technologies after completing the corresponding curriculum. In thematic analysis of qualitative data, fellows indicated that knowledge gains led to improved patient care. There was universal agreement about enjoyment and effectiveness of the curricula. Conclusions: TeKnO T1D proved to be an engaging, effective way to improve endocrinology fellows' knowledge and confidence about insulin pumps and CGM use in the management of pediatric type 1 diabetes. [ABSTRACT FROM AUTHOR]

The article presents an evaluation of an evidence-based hospital nursing education program related to subcutaneous insulin pump therapy for inpatient type I diabetes management, including topics such as patient safety, patient selection, and equipment. Statistical analysis of nurses' knowledge and confidence indicated that the program was effective in improving awareness and competence of insulin pump therapy.

Deals with the studies presented at the American Diabetes Association annual meeting held in San Diego, California from June 10 to 14, 2005. Discussion on basal insulin analogs; Review of a number of studies of glargine and of detemir; Presentation of a study on insulin pump therapy.

Presents information on several studies related to youth with type 1 diabetes to be presented at the 65th Scientific Sessions of the American Diabetes Association at the San Diego Convention Center in California from June 10 to 14, 2005. Use of insulin pumps in youth with type 1 diabetes; Possible association between fibrinogen genotype and subclinical complications of diabetes; Characterization of the nature of glucose abnormalities in cystic fibrosis patients.

Presents information on several studies related to new technology with regards to insulin delivery systems to be presented at the 65th Scientific Sessions of the American Diabetes Association at the San Diego Convention Center in California from June 10 to 14, 2005. Advantages of continuous subcutaneous insulin infusion; Comparison of inhalable Alveair with Aspart; Improved efficacy of intesulin formulated with unmodified regular insulin in normal rats.

Reports on the announcement by the FDA on the completion of the Class II recall of Paradigm Model 511 Insulin Infusion Pumps by Medtronic MiniMed, California. Initiation of recall by letters with involvement of all code numbers; Recall of devices due to entry of water into them when in prolonged contact with water causing devices to malfunction; Impact of recall on thousands of units distributed nationwide and in Canada.